Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The self-assembled skin substitute (SASS) is an autologous, bilayered tissue-engineered skin product developed by the Laboratoire d'Organogenèse Expérimentale (LOEX). It is produced using a unique scaffold-free "self-assembly" approach, where patient-derived fibroblasts are cultured to secrete and organize their own extracellular matrix, forming robust dermal sheets. Autologous keratinocytes are then seeded onto these sheets and cultured at the air-liquid interface to create a stratified and differentiated epidermis. This method avoids the use of exogenous materials like bovine collagen or synthetic polymers, resulting in a construct that closely mimics the mechanical and biological properties of native human skin. SASS is designed for the permanent closure of full-thickness skin wounds, particularly in patients with extensive burns where donor sites are limited, as well as for chronic ulcers and genetic skin conditions like dystrophic epidermolysis bullosa.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on self-assembled skin substitute.